Is Amarantus Bioscience Holdings Inc halal to invest in?

According to Musaffa's Shariah screening methodology, Amarantus Bioscience Holdings Inc (AMBS) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Amarantus Bioscience Holdings Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Amarantus Bioscience Holdings Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Amarantus Bioscience Holdings Inc?

Muslim investors may consider investing in Amarantus Bioscience Holdings Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Amarantus Bioscience Holdings Inc classified as NOT COVERED?

Musaffa determines the Shariah status of Amarantus Bioscience Holdings Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Amarantus Bioscience Holdings Inc updated?

The Shariah compliance status of Amarantus Bioscience Holdings Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Amarantus Bioscience Holdings Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Amarantus Bioscience Holdings Inc?

You can check the latest Shariah compliance status of Amarantus Bioscience Holdings Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Amarantus Bioscience Holdings Inc. Stock Analysis AMBS

United States Health Care Nano Cap

Amarantus BioScience Holdings, Inc. is a biopharmaceutical company, which engages in developing therapeutic products with the potential for orphan drug designation in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, and diagnostics in neurology. The company is headquartered in San Francisco, California. The company went IPO on 2008-09-29. The firm is focused on developing therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology and regenerative medicine. The firm owns or has licenses to various product candidates in the biopharmaceutical healthcare industry. The company has acquired the rights to the engineered skin substitute program (ESS), a regenerative medicine-based approach for treating severe burns with full-thickness autologous skin grown in tissue culture that is being pursued by Company’s wholly owned subsidiary Cutanogen Corporation. The Company’s wholly owned subsidiary MANF Therapeutics, Inc. owns intellectual property rights and licenses from a number of prominent universities related to the development of the therapeutic protein known as mesencephalic astrocyte-derived neurotrophic factor (MANF). MANF Therapeutics, Inc. is developing MANF-based products as treatments for ophthalmological disorders.

Financial Metrics & Statements of Amarantus Bioscience Holdings Inc (AMBS)

FAQ's for Amarantus Bioscience Holdings Inc (AMBS)

According to Musaffa’s Shariah screening methodology, Amarantus Bioscience Holdings Inc (AMBS) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.